Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | IP6K1 | Q92551 | 5/20 | 0.54 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.54 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744436 | 1.00 | PARP1 (0.61) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL3731351 | 0.80 | ACVR1 (0.60) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL162925 | 0.78 | PARP1 (0.49) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL6207587 | 0.77 | MKNK1 (0.60) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL11547422 | 0.77 | SRC (0.56) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| Quinazolinone SCHEMBL88525 | 0.76 | PARP1 (1.00) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| Quinazolinone SCHEMBL27983253 | 0.76 | PARP1 (1.00) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL12476626 | 0.75 | PARP1 (0.62) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL7980737 | 0.75 | ACVR1 (0.67) | PARP1SMN1; SMN2PDPK1CA12ALOX15 | |
| SCHEMBL10637102 | 0.75 | PARP1 (0.53) | PARP1SMN1; SMN2PDPK1CA12ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466942-A | Chiral secondary phosphine oxide compound, chiral quinazolinone/pyrimidinone ring derivative based on chiral secondary phosphine oxide compound and application of chiral quinazolinone/pyrimidinone ring derivative | 中山大学 | 2024-01-30 | — | — | CN | disclosed |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | Genetic Intelligence, Inc | 2023-08-31 | — | — | US | disclosed |
| EP-3789379-A1 | 4-PHENYLBENZO[G]QUINAZOLINE OR 4-(3,5-DIMETHYLPHENYLBENZO[G]QUINAZOLINE IRIDIUM COMPLEXES FOR USE AS NEAR-INFRARED OR INFRARED EMITTING MATERIALS IN OLEDS | Universal Display Corporation (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3321258-B1 | 4-PHENYLBENZO[G]QUINAZOLINE OR 4-(3,5-DIMETHYLPHENYLBENZO[G]QUINAZOLINE IRIDIUM COMPLEXES FOR USE AS NEAR-INFRARED OR INFRARED EMITTING MATERIALS IN OLEDS | UNIVERSAL DISPLAY CORP (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3321258-A1 | 4-PHENYLBENZO[G]QUINAZOLINE OR 4-(3,5-DIMETHYLPHENYLBENZO[G]QUINAZOLINE IRIDIUM COMPLEXES FOR USE AS NEAR-INFRARED OR INFRARED EMITTING MATERIALS IN OLEDS | Universal Display Corporation (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180130956-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2018-05-10 | — | — | US | disclosed |
| EP-0882717-B1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2008147852-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-04 | — | — | WO | disclosed |
| US-6750218-B2 | INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | MILLENNIUMIUM PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | MATSUNO KENJI (JP) | 2003-12-11 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6335344-B1 | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases | PFIZER INC. | 2002-01-01 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0907642-A1 | PHENYLAMINO-SUBSTITUTED TRICYCLIC DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | PFIZER INC. (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997049688-A1 | PHENYLAMINO-SUBSTITUTED TRICYCLIC DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | PFIZER INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-4134981-A | ANTIALLERGENS | PFIZER INC. (US) | 1979-01-16 | — | — | US | disclosed |
| US-4120962-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4044134-A | FUSED WITH QUINOLINE OR PYRIDINE, 2-METHYL, ETHYL, OR ACETYL GROUP | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3974161-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | ERBB4, NPR1, PDGFRB | PARP1 2539/4885SMN1; SMN2 3739/4885PDPK1 1208/4885 |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | PARP1 2183/4885SMN1; SMN2 3955/4885PDPK1 1227/4885 |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | TARDBP, FUS, RBM17 | PARP1 3581/4885SMN1; SMN2 65/4885PDPK1 3681/4885 |
| US-20180130956-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | CYCS, OXA1L, ICOSLG | PARP1 1669/4885SMN1; SMN2 4698/4885PDPK1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.